Foghorn Therapeutics (FHTX) Total Non-Current Liabilities (2020 - 2026)

Foghorn Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $298.1 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 6.69% year-over-year to $298.1 million in Q1 2026; TTM through Mar 2026 was $298.1 million, a 6.69% decrease from a year earlier, with the FY2025 full-year figure at $306.0 million, down 7.12% from the prior year.
• Total Non-Current Liabilities eased to $298.1 million in Q1 2026 per FHTX's latest filing, from $306.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $415.8 million in Q1 2022 and bottomed at $294.0 million in Q3 2025.
• The 5-year median for Total Non-Current Liabilities is $367.0 million (2023), against an average of $357.8 million.
• Across the five-year window, Total Non-Current Liabilities surged 290.36% in 2022 and fell 10.29% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $404.7 million in 2022, then decreased by 10.29% to $363.1 million in 2023, then decreased by 9.25% to $329.5 million in 2024, then fell by 7.12% to $306.0 million in 2025, then slipped by 2.59% to $298.1 million in 2026.
• Per Business Quant, the three latest FHTX Total Non-Current Liabilities figures stand at $298.1 million (Q1 2026), $306.0 million (Q4 2025), and $294.0 million (Q3 2025).